Understanding how immune cells fight triple-negative breast cancer
Elucidate the role of B/T cell-enriched immune aggregates in immune surveillance against TNBC
This study is looking at how certain immune cells, called B and T cells, help the body spot and fight early signs of triple-negative breast cancer, using a special mouse model to learn more about how these cells work together and how we might boost our natural defenses against cancer.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Virginia NIH-funded |
| Lab location | 1 site (Charlottesville, United States) |
| Project ID | NIH-11037137 on NIH RePORTER |
What this research studies
This research investigates the role of immune cells, specifically B and T cells, in recognizing and combating early stages of triple-negative breast cancer (TNBC). Using a specialized mouse model, researchers will observe how these immune cells interact with pre-cancerous cells over time. The study aims to uncover the mechanisms of immune surveillance that may fail in cancer development, providing insights into how to enhance the body's natural defenses against cancer. By examining immune aggregates formed by these cells, the research seeks to identify potential therapeutic targets for improving cancer treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals at high risk for developing triple-negative breast cancer, particularly those with BRCA1 mutations or a family history of breast cancer.
Not a fit: Patients with established triple-negative breast cancer or those who do not have genetic predispositions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for enhancing immune responses against triple-negative breast cancer, potentially improving patient outcomes.
How similar studies have performed: Previous research has shown promising results in understanding immune responses in cancer, but this specific approach using the MADM model is relatively novel.
Where this research is happening
Charlottesville, United States
- University of Virginia — Charlottesville, United States (Active)
Researchers
- Principal investigator: Zong, Hui — University of Virginia
- Study coordinator: Zong, Hui
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.